Long-COVID incidence proportion in adults and children between 2020 and 2024.

IF 8.2 1区 医学 Q1 IMMUNOLOGY Clinical Infectious Diseases Pub Date : 2025-02-05 DOI:10.1093/cid/ciaf046
Hannah Mandel, Yun J Yoo, Andrea J Allen, Sajjad Abedian, Zoe Verzani, Elizabeth W Karlson, Lawrence C Kleinman, Praveen C Mudumbi, Carlos R Oliveira, Jennifer A Muszynski, Rachel S Gross, Thomas W Carton, C Kim, Emily Taylor, Heekyong Park, Jasmin Divers, J Daniel Kelly, Jonathan Arnold, Carol Reynolds Geary, Chengxi Zang, Kelan G Tantisira, Kyung E Rhee, Michael Koropsak, Sindhu Mohandas, Andrew Vasey, Abu Saleh Mohammad Mosa, Melissa Haendel, Christopher G Chute, Shawn N Murphy, Lisa O'Brien, Jacqueline Szmuszkovicz, Nicholas Guthe, Jorge L Santana, Aliva De, Amanda L Bogie, Katia C Halabi, Lathika Mohanraj, Patricia A Kinser, Samuel E Packard, Katherine R Tuttle, Kathryn Hirabayashi, Rainu Kaushal, Emily Pfaff, Mark G Weiner, Lorna E Thorpe, Richard A Moffitt
{"title":"Long-COVID incidence proportion in adults and children between 2020 and 2024.","authors":"Hannah Mandel, Yun J Yoo, Andrea J Allen, Sajjad Abedian, Zoe Verzani, Elizabeth W Karlson, Lawrence C Kleinman, Praveen C Mudumbi, Carlos R Oliveira, Jennifer A Muszynski, Rachel S Gross, Thomas W Carton, C Kim, Emily Taylor, Heekyong Park, Jasmin Divers, J Daniel Kelly, Jonathan Arnold, Carol Reynolds Geary, Chengxi Zang, Kelan G Tantisira, Kyung E Rhee, Michael Koropsak, Sindhu Mohandas, Andrew Vasey, Abu Saleh Mohammad Mosa, Melissa Haendel, Christopher G Chute, Shawn N Murphy, Lisa O'Brien, Jacqueline Szmuszkovicz, Nicholas Guthe, Jorge L Santana, Aliva De, Amanda L Bogie, Katia C Halabi, Lathika Mohanraj, Patricia A Kinser, Samuel E Packard, Katherine R Tuttle, Kathryn Hirabayashi, Rainu Kaushal, Emily Pfaff, Mark G Weiner, Lorna E Thorpe, Richard A Moffitt","doi":"10.1093/cid/ciaf046","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Incidence estimates of post-acute sequelae of SARS-CoV-2 infection, also known as long-COVID, have varied across studies and changed over time. We estimated long-COVID incidence among adult and pediatric populations in three nationwide research networks of electronic health records (EHR) participating in the RECOVER Initiative using different classification algorithms (computable phenotypes).</p><p><strong>Methods: </strong>This EHR-based retrospective cohort study included adult and pediatric patients with documented acute SARS-CoV-2 infection and two control groups-- contemporary COVID-19 negative and historical patients (2019). We examined the proportion of individuals identified as having symptoms or conditions consistent with probable long-COVID within 30-180 days after COVID-19 infection (incidence proportion). Each network (the National COVID Cohort Collaborative (N3C), National Patient-Centered Clinical Research Network (PCORnet), and PEDSnet) implemented its own long-COVID definition. We introduced a harmonized definition for adults in a supplementary analysis.</p><p><strong>Results: </strong>Overall, 4% of children and 10-26% of adults developed long-COVID, depending on computable phenotype used. Excess incidence among SARS-CoV-2 patients was 1.5% in children and ranged from 5-6% among adults, representing a lower-bound incidence estimation based on our control groups. Temporal patterns were consistent across networks, with peaks associated with introduction of new viral variants.</p><p><strong>Conclusion: </strong>Our findings indicate that preventing and mitigating long-COVID remains a public health priority. Examining temporal patterns and risk factors of long-COVID incidence informs our understanding of etiology and can improve prevention and management.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cid/ciaf046","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Incidence estimates of post-acute sequelae of SARS-CoV-2 infection, also known as long-COVID, have varied across studies and changed over time. We estimated long-COVID incidence among adult and pediatric populations in three nationwide research networks of electronic health records (EHR) participating in the RECOVER Initiative using different classification algorithms (computable phenotypes).

Methods: This EHR-based retrospective cohort study included adult and pediatric patients with documented acute SARS-CoV-2 infection and two control groups-- contemporary COVID-19 negative and historical patients (2019). We examined the proportion of individuals identified as having symptoms or conditions consistent with probable long-COVID within 30-180 days after COVID-19 infection (incidence proportion). Each network (the National COVID Cohort Collaborative (N3C), National Patient-Centered Clinical Research Network (PCORnet), and PEDSnet) implemented its own long-COVID definition. We introduced a harmonized definition for adults in a supplementary analysis.

Results: Overall, 4% of children and 10-26% of adults developed long-COVID, depending on computable phenotype used. Excess incidence among SARS-CoV-2 patients was 1.5% in children and ranged from 5-6% among adults, representing a lower-bound incidence estimation based on our control groups. Temporal patterns were consistent across networks, with peaks associated with introduction of new viral variants.

Conclusion: Our findings indicate that preventing and mitigating long-COVID remains a public health priority. Examining temporal patterns and risk factors of long-COVID incidence informs our understanding of etiology and can improve prevention and management.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Infectious Diseases
Clinical Infectious Diseases 医学-传染病学
CiteScore
25.00
自引率
2.50%
发文量
900
审稿时长
3 months
期刊介绍: Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.
期刊最新文献
Antiviral Trials-Navigating the Shifting Sands of a Pandemic. Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial. American Thoracic Society/Centers for Disease Control and Prevention/European Respiratory Society/Infectious Diseases Society of America (ATS/CDC/ERS/IDSA) Updated guideline on the treatment of tuberculosis. Correction to: State-of-the-Art Review: Diagnosis and Management of Spinal Implant Infections. The importance of antibiofilm antibiotics in hardware-associated infections.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1